Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Stiefel, a GSK Company
With
GlaxoSmithKline
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female subjects at least 12 years old and in good general health.
Mild to moderate plaque-type psoriasis
You may not be if
Known allergy or other adverse reaction to calcipotriene or other vitamin D analogs; or to any component of the investigational formulations
History of hypercalcemia or of vitamin D toxicity.
Diagnosis of generalized pustular or erythrodermic exfoliative psoriasis.
Other serious skin disorder or any chronic medical condition that is not well controlled.
Use of non-biologic systemic anti-psoriatic therapy or biologic therapy within four weeks of enrollment.
Use of topical therapies that have a known beneficial effect on psoriasis, within 2 weeks of enrollment.
Systemic medications for other medical conditions that are known to affect psoriasis within the past four weeks of enrollment.
Use of any investigational therapy within 4 weeks of enrollment.
Pregnant women, women who are breast feeding, or sexually active women of child bearing potential who are not practicing an acceptable method of birth control.
Clareo Health | Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies
